2009
DOI: 10.1038/tpj.2009.34
|View full text |Cite
|
Sign up to set email alerts
|

Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52 000 individuals

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
14
1

Year Published

2010
2010
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(15 citation statements)
references
References 26 publications
0
14
1
Order By: Relevance
“…However, for ischemic heart disease, a decreased risk was detected in a cross-sectional study with a hazard ratio of 0.9 (0.8-1.0), which remained significant after multifactorial adjustment. However, the finding could not be confirmed in a large prospective study or in a large case-control study with enough power to exclude even minor changes of risk with 90% power [78]. The lack of association between CYP2C9 and risk of ischemic vascular disease in this study is in accordance with other studies [79][80][81][82].…”
Section: Cyp2c9 and Risk Of Ischemic Vascular Diseasecontrasting
confidence: 49%
See 1 more Smart Citation
“…However, for ischemic heart disease, a decreased risk was detected in a cross-sectional study with a hazard ratio of 0.9 (0.8-1.0), which remained significant after multifactorial adjustment. However, the finding could not be confirmed in a large prospective study or in a large case-control study with enough power to exclude even minor changes of risk with 90% power [78]. The lack of association between CYP2C9 and risk of ischemic vascular disease in this study is in accordance with other studies [79][80][81][82].…”
Section: Cyp2c9 and Risk Of Ischemic Vascular Diseasecontrasting
confidence: 49%
“…Atherosclerosis is a key process in the development of ischemic vascular disease such as ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease and ischemic stroke. Kaur-Knudsen et al [78] found no difference in subclinical atherosclerosis across CYP2C9*2 and CYP2C9*3 genotype when comparing ankle brachial blood pressure index as a marker for peripheral arterial disease, or in plasma concentration of C-reactive protein as a marker of inflammation. Kaur-Knudsen et al also did not detect any change of risk of myocardial infarction, ischemic cerebrovascular disease, or ischemic stroke across CYP2C9 genotype in two large population studies (Fig.…”
Section: Cyp2c9 and Risk Of Ischemic Vascular Diseasementioning
confidence: 98%
“…The use of CYP2C9 substrates and inhibitors was associated with a significant increase in the risk of myocardial infarction especially in female harbouring a variant allele (CYP2C8*2, CYP2C9*3) [60]. No association between CYP2C9*2 and CYP2C9*3 polymorphisms and risk of subclinical atherosclerosis, ischemic vascular disease (ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease and ischemic stroke) or cardiovascular death was found in a very large Danish study [61]. Similarly, an association with coronary atherosclerosis, detected by angiography, was found in a small study performed in Turky [62].…”
Section: Cyp2c8 Cyp2c9 Hypertension and Cardiovascular Diseasesmentioning
confidence: 93%
“…19 Sex hormones such as estrogens protect against oxidative stress and are known to be vasoprotective. [20][21][22] In recent years, several studies have investigated the association between CYP17A1 heritable variation and CAD. 7,23 However, the relationship between CYP 17A1 genetic polymorphisms and CAD in the Uygur population remains unclear.…”
Section: Introductionmentioning
confidence: 99%